Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Predictive V16alue of Thymidylate Synthase Expression in Gastric Cancer: A Systematic Review with Meta-analysis

  • Hu, Hua-Bin (Department of Oncology, Xiangya Hospital of Central South University) ;
  • Kuang, Lei (Department of Gastroenterology, Nanfang Hospital of Southern Medical University) ;
  • Zeng, Xiao-Min (Department of Epidemiology and Statistics, School of Public Health of Central South University) ;
  • Li, Bin (Department of Oncology, Xiangya Hospital of Central South University) ;
  • Liu, En-Yi (Department of Oncology, Xiangya Hospital of Central South University) ;
  • Zhong, Mei-Zuo (Department of Oncology, Xiangya Hospital of Central South University)
  • Published : 2012.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The relationship between thymidylate synthase (TS) expression and outcomes in gastric cancer (GC) patients remains controversial, although most studies reported poor survival and reduced response to fluoropyrimidine were related to high TS in tumors. We carried out a systematic review of the literature with meta-analysis to estimate the predictive value of TS expression from published studies. Methods: We indentified 24 studies analysing the outcome data in gastric cancer stratified by TS expression. Effect measures of outcome were hazard ratios (HRs) for overall survival (OS) and event-free survival (EFS), or the odds ratio (OR) for overall response rate (ORR). HRs and ORs from these eligible studies were pooled using random-effects meta-analysis. Results: Fifteen studies investigated outcomes in a total of 844 patients with advanced GC, and nine studies investigated outcomes in a total of 1,235 patients with localized GC undergoing adjuvant therapy. Meta-analysis of estimates showed high TS expression was significantly associated with poor OS in the advanced setting (HR: 1.43, 95%CI: 1.08 - 1.90), and poor EFS in the adjuvant setting (HR: 1.53, 95%CI: 1.01 - 2.32). Subgroup analysis demonstrated TS expression to haves even greater value in predicting OS, EFS and ORR in advanced GC patients treated with fluoropyrimidine monotherapy (HR for OS: 2.32, 95%CI: 1.53 - 3.50; HR for EFS: 1.76, 95%CI: 1.19 - 2.60; OR for ORR: 0.32, 95%CI: 0.11 - 0.95). Conclusion: High levels of TS expression were asssociated with a poorer OS for advanced GC patients compared with low levels. In the adjuvant setting, high TS expression was also associated with a worse EFS. Additional studies with consistent methodology are needed to define the precise predictive value of TS.

Keywords

References

  1. Akamoto S, Usuki H, Haba R, et al (2008). The discrepancy in thymidylate synthase and dihydropyrimidine dehydrogenase expression depending on measurement methodologies in stage 4 gastric cancer. Hepatogastroenterology, 55, 1882-6.
  2. Altman DG, Lausen B, Sauerbrei W, et al (1994). Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst, 86, 829-35. https://doi.org/10.1093/jnci/86.11.829
  3. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  4. Berger SH, Jenh CH, Johnson LF, et al (1985). Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol, 28, 461-7.
  5. Boku N, Chin K, Hosokawa K, et al (1998). Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cisplatinum. Clin Cancer Res, 4, 1469-74.
  6. Boku N, Ohtsu A, Yoshida S, et al (2007). Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol, 37, 275-81. https://doi.org/10.1093/jjco/hym015
  7. Cho MY, Yi SY, Eom M, et al (2006). A high thymidylate synthase expression is related to better outcome for advanced gastric cancer patients treated with 5-FU chemotherapy after curative resection. Korean J Pathol, 40, 128-36.
  8. Choi IS, Lee HS, Lee KW, et al (2011). Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes. Med Oncol, 28, 991-8 https://doi.org/10.1007/s12032-010-9590-4
  9. Choi J, Lim H, Nam DK, et al (2001). Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer, 84, 186-92. https://doi.org/10.1054/bjoc.2000.1553
  10. Chung-Kang C, Ohno M, Nishimura K, et al (2006). Intratumoral heterogeneous expression of thymidylate synthase in gastric cancer. Hepatogastroenterology, 53, 458-62.
  11. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  12. Fukuda H, Takiguchi N, Koda K, et al (2006). Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest, 24, 235-41. https://doi.org/10.1080/07357900600632082
  13. Hayden JA, Cote P, Bombardier C (2006). Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med, 144, 427-37 https://doi.org/10.7326/0003-4819-144-6-200603210-00010
  14. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  15. Hua D, Huang ZH, Mao Y, et al (2007). Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol, 13, 5030-4. https://doi.org/10.3748/wjg.v13.i37.5030
  16. Ichikawa W, Takahashi T, Suto K, et al (2004). Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer, 91, 1245-50. https://doi.org/10.1038/sj.bjc.6602139
  17. Ichikawa W, Takahashi T, Suto K, et al (2006). Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer, 119, 1927-33. https://doi.org/10.1002/ijc.22080
  18. Ishido K, Azuma M, Koizumi W, et al (2009). Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy. Pharmacogenet Genomics, 2009, Nov 5.
  19. Ishikawa Y, Kubota T, Otani Y, et al (1999). Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res, 19, 5635-40.
  20. Ishizone S, Maruta F, Saito H, et al (2006). Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy, 52, 301-7. https://doi.org/10.1159/000096002
  21. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  22. Jeung HC, Rha SY, Shin SJ, et al (2011). Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anticancer Drugs, 22, 801-10. https://doi.org/10.1097/CAD.0b013e328345c9ae
  23. Jeong SH, Han JH, Kim JH, et al (2011). Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci, 56, 131-8. https://doi.org/10.1007/s10620-010-1280-8
  24. Johnston PG, Drake JC, Trepel J, et al (1992). Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res, 52, 4306-12.
  25. Kim KH, Kwon HC, Oh SY, et al (2011). Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers, 16, 74-82. https://doi.org/10.3109/1354750X.2010.533284
  26. Kim JS, Kim MA, Kim TM, et al (2009). Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer, 100, 732-8. https://doi.org/10.1038/sj.bjc.6604936
  27. Koizumi W, Narahara H, Hara T, et al (2008). S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol, 9, 215-21. https://doi.org/10.1016/S1470-2045(08)70035-4
  28. Koizumi W, Tanabe S, Azuma M, et al (2010). Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int J Cancer, 126, 162-70. https://doi.org/10.1002/ijc.24726
  29. Kuniyasu T, Nakamura T, Tabuchi Y, et al (1998). Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. CANCER, 83, 1300-6. https://doi.org/10.1002/(SICI)1097-0142(19981001)83:7<1300::AID-CNCR5>3.0.CO;2-M
  30. Kwon HC, Roh MS, Oh SY, et al (2007). Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol, 18, 504-9. https://doi.org/10.1093/annonc/mdl430
  31. Lenz HJ, Leichman CG, Danenberg KD, et al (1996). Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol, 14, 176-82. https://doi.org/10.1200/JCO.1996.14.1.176
  32. Lee J, Park CK, Park JO, et al (2008). Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res, 14, 82-8. https://doi.org/10.1158/1078-0432.CCR-07-0612
  33. Liu JM, Chen LT, Li AF, et al (2004). Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy. Jpn J Clin Oncol, 34, 727-32. https://doi.org/10.1093/jjco/hyh137
  34. Matsubara J, Nishina T, Yamada Y, et al (2008). Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer, 98, 832-9. https://doi.org/10.1038/sj.bjc.6604211
  35. Metzger R, Leichman CG, Danenberg KD, et al (1998). ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol, 16, 309-16. https://doi.org/10.1200/JCO.1998.16.1.309
  36. Miyamoto S, Boku N, Ohtsu A, et al (2000). Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. Int J Oncol, 17, 653-8.
  37. Napieralski R, Ott K, Kremer M, et al (2005). Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res, 11, 3025-31. https://doi.org/10.1158/1078-0432.CCR-04-1605
  38. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  39. Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N ENGL J MED, 357, 1810-20. https://doi.org/10.1056/NEJMoa072252
  40. Santi DV, McHenry CS, Sommer H (1974). Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry, 13, 471-81. https://doi.org/10.1021/bi00700a012
  41. Suda Y, Kuwashima Y, Tanaka Y, et al (1999). Expression of thymidylate synthase and thymidine phosphorylase in recurrence and survival rates of advanced gastric cancer. Gastric Cancer, 2, 165-72. https://doi.org/10.1007/s101200050041
  42. Tahara M, Ochiai A, Fujimoto J, et al (2004). Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncol Rep, 11, 9-15.
  43. Terashima M, Fujiwara H, Takagane A, et al (2003). Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer, 1, 71-81.
  44. Tsujitani S, Konishi I, Suzuki K, et al (2000). Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients. J Exp Clin Cancer Res, 19, 189-95.
  45. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7 https://doi.org/10.1200/JCO.2006.06.8429
  46. Wei J, Zou Z, Qian X, et al (2008). ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer, 98, 1398-402. https://doi.org/10.1038/sj.bjc.6604317
  47. Yeh CN, Jung SM, Chen TW, et al (2010). Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracilbased adjuvant chemotherapy. Langenbecks Arch Surg, 395, 217-25. https://doi.org/10.1007/s00423-009-0573-x
  48. Yeh KH, Shun CT, Chen CL, et al (1998). High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer, 82, 1626-31. https://doi.org/10.1002/(SICI)1097-0142(19980501)82:9<1626::AID-CNCR5>3.0.CO;2-8

Cited by

  1. Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer vol.30, pp.2, 2013, https://doi.org/10.1007/s12032-013-0545-4
  2. /M Phase and Growth Inhibition in SGC-7901 Gastric Cancer Cells vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6437
  3. Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase vol.17, pp.1, 2014, https://doi.org/10.1007/s10120-013-0249-7
  4. Thymidylate Synthase Polymorphisms and Risk of Lung Cancer among the Jordanian Population: a Case Control Study vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8287
  5. Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy vol.48, pp.6, 2016, https://doi.org/10.3892/ijo.2016.3484